Parotitis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Changes made per Mahshid's request |
||
| Line 19: | Line 19: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Glands]] | [[Category:Glands]] | ||
[[Category:Inflammations]] | [[Category:Inflammations]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:38, 18 September 2017
|
Parotitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parotitis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Parotitis future or investigational therapies |
|
Risk calculators and risk factors for Parotitis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.
Overview
Aprotinin, a kallikrein inhibitor, is currently being investigated for treatment of chronic parotitis symptoms. Initial studies have demonstrated its potential to relieve pain, restore normal parotid gland function, and resolve parotid gland swelling. Further research is warranted.
Future or Investigational Therapies
- Aprotinin, a kallikrein inhibitor, is currently being investigated for treatment of chronic parotitis symptoms.[1]
- Kallikrein release in the parotid gland is associated with the inflammatory edema process.
- Aprotinin was administered to 7 recurrent parotitis patients, with the following results observed:
- Pain relieved 12 hours after administration
- Parotid gland function returned to normal 48 hours after administration
- Parotid gland swelling resolved after 7 days.
- More research is warranted on the efficacy of kallikrein inhibition.